- Home
- ENGN vs PRQR Comparison
ENGN vs PRQR Comparison
Compare ENGN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENGN | PRQR |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | Canada | Netherlands |
| Employees | 82 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 647.1M | 166.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ENGN | PRQR |
|---|---|---|
| Price | $7.23 | $1.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $21.00 | $7.67 |
| AVG Volume (30 Days) | ★ 479.7K | 285.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.66 | $1.08 |
| 52 Week High | $12.25 | $3.10 |
Technical Indicators
Market Signals| Indicator | ENGN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 34.06 | 54.26 |
| Support Level | $6.03 | $1.65 |
| Resistance Level | $7.33 | $1.80 |
| Average True Range (ATR) | 0.63 | 0.10 |
| MACD | -0.27 | 0.03 |
| Stochastic Oscillator | 16.98 | 53.00 |
Price Performance
Historical ComparisonAbout ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.